We­govy woes con­tin­ue as man­u­fac­tur­ing is­sues will lead to fur­ther short­age of Novo's obe­si­ty drug

As the new year rapid­ly ap­proach­es, and gyms and health food stores across Amer­i­ca pre­pare for a wave of peo­ple seek­ing weight loss, No­vo Nordisk has an­nounced that it does not ex­pect to meet de­mand for We­govy, its pre­scrip­tion in­jectable weight-loss med­ica­tion for obe­si­ty, un­til the sec­ond half of 2022 in the US.

The short­age comes due to man­u­fac­tur­ing is­sues at a con­tract man­u­fac­tur­er that was tasked with fill­ing sy­ringes for the pens. The news comes just days af­ter No­vo an­nounced that it would in­vest rough­ly $2.58 bil­lion to ex­pand its man­u­fac­tur­ing hub in Kalund­borg, Den­mark with three new fa­cil­i­ties and the ex­pan­sion of a fourth to keep up with the suc­cess of its di­a­betes and obe­si­ty med semaglu­tide, We­govy and Ry­bel­sus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.